What is CYP3A5?
The CYP3A5 gene is the blueprint for an enzyme that, along with CYP3A4, is responsible for processing a large portion of the medications we use today. What’s unique about CYP3A5 is that a large portion of the European population naturally produces very little of it (the so-called “non-expressors”). Your CYP3A5 status is genetically determined and remains unchanged throughout your life.
The gene determines whether your liver activates this specific enzyme, and to what extent. This has a direct and often significant impact on how quickly certain medications are cleared from your blood.
Why test your CYP3A5 status?
Gaining insight into your CYP3A5 profile is medically essential when using specific, high-stakes medications where maintaining the correct blood concentration is critical:
- Optimal Dosing of Immunosuppressants: For drugs such as tacrolimus (commonly used after transplants), the CYP3A5 enzyme largely determines the required dosage. ‘Expressors’ often require significantly higher doses than ‘non-expressors’ to prevent organ rejection.
- Preventing Toxicity: If you are a ‘non-expressor’ (slow metabolism) and receive a standard dose based on the population average, your blood levels can become dangerously high. This increases the risk of severe side effects and kidney damage.
- Effectiveness of Chemotherapy: Certain oncology-related drugs are metabolized by this enzyme; overly rapid metabolism can undermine the overall effectiveness of the treatment.
Medications influenced by CYP3A5
The functioning of CYP3A5 is particularly critical for the following agents:
- Immunosuppressants: including Tacrolimus (Prograf, Advagraf), Cyclosporine, and Sirolimus.
- Oncology: including Vincristine and Cyclophosphamide.
- Statins (Cholesterol-lowering drugs): including Atorvastatin and Simvastatin (in conjunction with CYP3A4).
- Antihypertensives (Blood pressure medication): including Nifedipine and Felodipine.
- Antifungals: including Voriconazole.
Interpretation of your CYP3A5 status
Based on your DNA, it is determined whether you are an ‘Expressor’ or a ‘Non-expressor’. This status dictates how your body responds to the aforementioned medication:
| Result | Interpretatie | Interpretation |
|---|---|---|
| PM | Poor Metabolizer (Non-expressor) | The enzyme is inactive. This is the case for most Europeans. You have an increased risk of side effects with standard doses of specific medications. |
| IM | Intermediate Metabolizer | The enzyme exhibits limited activity. Medication processing is slower than average, often requiring careful dosing. |
| NM | Normal Metabolizer (Expressor) | The enzyme is active and functioning normally. Certain medications (such as tacrolimus) are broken down more quickly, so a higher dose is often required for effectiveness. |
| UM | Ultrarapid Metabolizer | The enzyme works extremely quickly. Medication is removed from the body very quickly, which increases the risk of insufficient effectiveness of the therapy. |
Medical interpretation & advice
The results of your Easly test are cross-referenced with the official medication guidelines of the KNMP (G-Standaard). This provides you, your pharmacist, and your physician with a scientific foundation for a tailored treatment plan.
Important: Always use this result in consultation with your treating physician or pharmacist. Never adjust your dosage independently. Based on your profile, a physician or pharmacist may decide to optimize the dose or switch to a medication that does not depend on this specific enzyme.
Do you want to know if your symptoms can be explained by your DNA profile? Take the free Pharmacogenetic Quickscan (Dutch only) and receive immediate clarity on whether a test would be beneficial for you.
